CDK4 and cancer: CDK4/6 inhibitor resistance [19] might be overcome by additional MEK inhibition [20], and several clinical trials of CDK4/6 inhibitors such as ribociclib or palbociclib with MEK inhibitors such as trametinib and bimetinib are currently ongoing in various cancer models [20].